Idiopathic Adult Growth Hormone Deficiency
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
GH secretion is controlled by hypothalamic as well as intrapituitary and peripheral signals, all of which converge upon the somatotroph, resulting in integrated GH synthesis and secretion. Enabling an accurate diagnosis of idiopathic adult GH deficiency (IAGHD) is challenged by the pulsatility of GH secretion, provocative test result variability, and suboptimal GH assay standardization. The spectrum between attenuated GH secretion associated with the normal aging process and with obesity and truly well-defined IAGHD is not distinct and may mislead the diagnosis. Adult-onset GHD is mainly caused by an acquired pituitary deficiency, commonly including prior head/neck irradiation, or an expanding pituitary mass causing functional somatotroph compression. To what extent rare cryptic causes account for those patients seemingly classified as IAGHD is unclear. About 15% of patients with adult GHD and receiving GH replacement in open-label surveillance studies are reported as being due to an idiopathic cause. These patients may also reflect a pool of subjects with an as yet to be determined occult defect, or those with unclear or incomplete medical histories (including forgotten past sports head injury or motor vehicle accident). Therefore, submaximal diagnostic evaluation likely leads to an inadvertent diagnosis of IAGHD. In these latter cases, adherence to rigorous biochemical diagnostic criteria and etiology exclusion may result in reclassification of a subset of these patients to a distinct known acquired etiology, or as GH-replete. Accordingly, rigorously verified IAGHD likely comprises less than 10% of adult GHD patients, an already rare disorder. Regardless of etiology, patients with adult GHD, including those with IAGHD, exhibit a well-defined clinical phenotype including increased fat mass, loss of lean muscle mass, decreased bone mass, and enhanced cardiac morbidity. Definition of unique efficacy and dosing parameters for GH replacement and resultant therapeutic efficacy markers in true IAGHD requires prospective study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while lean body mass improves by up to 7% during the first year of GH replacement (167,168).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [167]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326 · cited 2×
“The description of the adult GHD syndrome was rigorously defined in 1992 (1, 43, 44).”
BackgroundGiustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253 · cited 1×
“Declining GH pulse amplitude, rather than frequency, already starts occurring at the transition to young adulthood (13), and GH continues to decline thereafter with aging.”
BackgroundMelmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160 · cited 1×
“2006;355:2558–2573 (81), with permission.”
Self-citationMolitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Williams Textbook of Endocrinology
Reutrakul, S. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000323673.44568.e8 · Cited by 711
Acromegaly pathogenesis and treatment
Melmed, S. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39375 · Cited by 687
Self-citationHo, K. K. Y., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0631 · Cited by 615
Schneider, H. J., Kreitschmann-Andermahr, I., Ghigo, E., Stalla, G. K., & Agha, A. (2007) · JAMA · doi:10.1001/jama.298.12.1429 · Cited by 549 · cited 1×
“For example, GHD has been reported by 1 group in patients with primary hyperparathyroidism (58) and also after subarachnoid hemorrhage (56).”
BackgroundThe effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationInfluence of body weight on bone mass, architecture and turnover
Iwaniec, U. T., & Turner, R. T. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0089 · Cited by 199
“An age-related decrease in growth hormone secretion (Melmed 2013, Sattler 2013) contributes to muscle atrophy and bone loss in humans (Kuzma et al.”
Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults
Melmed, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1817346 · Cited by 173
Self-citationBasu, R., Qian, Y., & Kopchick, J. J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0018 · Cited by 72
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 71
Skin manifestations of growth hormone-induced diseases
Kanaka‐Gantenbein, C., Kogia, C., Abdel‐Naser, M. B., & Chrousos, G. P. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9378-8 · Cited by 57
Metabolic alterations in paediatric GH deficiency
Rothermel, J., & Reinehr, T. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.11.004 · Cited by 54
Pituitary Medicine From Discovery to Patient-Focused Outcomes
Melmed, S. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3653 · Cited by 47
Self-citationKim, J. H., Chae, H. W., Chin, S. O., Ku, C. R., Park, K. H., Lim, D. J., Kim, K. J., Lim, J. S., Kim, G., Choi, Y. M., et al. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.272 · Cited by 52
“Patients should be started on low doses, since side effects are dose-dependent [32].”
BackgroundMetabolic Syndrome in Hypopituitarism
Miljić, D., & POPOVIC, V. M. (2018) · Frontiers of hormone research · doi:10.1159/000485997 · Cited by 42
An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management
Iglesias, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206161 · Cited by 43
“The usual starting dose in adults is 0.2 to 0.4 mg daily subcutaneously (0.1 to 0.2 mg daily in those over 60 years of age), with increases of 0.1 to 0.2 mg daily every 6 weeks until serum IGF-1 levels are in the upper part of the normal range [116,199,200].”
BackgroundInfluentialGrowth hormone deficiency and human immunodeficiency virus
Rochira, V., & Guaraldi, G. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.02.006 · Cited by 34
“Signs, symptoms, and clinical markers of GHD are, however, non-specific [33], and their specificity loses strength in the context of HIV infection as most of them (bone and muscle mass loss, increased adiposity, impaired quality of life, low energy, and mood disorders) ar e part of the clinical features of HIV infecti…”
BackgroundMethodInfluentialUpdate on GH therapy in adults
Boguszewski, C. L. (2017) · F1000Research · doi:10.12688/f1000research.12057.1 · Cited by 29
Isolated anterior pituitary dysfunction in adulthood
Prencipe, N., Marinelli, L., Varaldo, E., Cuboni, D., Berton, A. M., Bioletto, F., Bona, C., Gasco, V., & Grottoli, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1100007 · Cited by 32
Reusch, C. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4456-5.00002-x · Cited by 32
Profka, E., Rodari, G., Giacchetti, F., & Giavoli, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678778 · Cited by 27
“In this setting, the diagnosis can be extremely challenging due to its subtle manifestations and only an extended use of dynamic GH test may reveal such condition (6, 7).”
BackgroundTakahashi, Y. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101816 · Cited by 29
Growth hormone should be used only for approved indications
Clemmons, D. R., Molitch, M., Hoffman, A. R., Klibanski, A., Strasburger, C. J., Kleinberg, D. L., Ho, K., Webb, S. M., Bronstein, M. D., Bouillon, R., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4187 · Cited by 23
“2013-4187 J Clin Endocrinol Metab, February 2014, 99(2):409–411 jcem.”
BackgroundInfluentialCórdoba‐Chacón, J., Gahete, M. D., Pokala, N., Geldermann, D., Alba, M., Salvatori, R., Luque, R. M., & Kineman, R. D. (2014) · Endocrinology · doi:10.1210/en.2013-1825 · Cited by 25
Doknić, M., Pekić, S., Miljić, D., Soldatović, I., POPOVIC, V. M., Stojanović, M., & Petakov, M. S. (2017) · International Journal of Endocrinology · doi:10.1155/2017/6969286 · Cited by 24
“An idiopathic cause is reported in about 10–15% of the patients with adult GHD in global surveillance studies [49].”
BackgroundSevere growth hormone deficiency and empty sella in obesity: a cross-sectional study
Lubrano, C., Tenuta, M., Costantini, D., Specchia, P., Bárbaro, G., Basciani, S., Mariani, S., Pontecorvi, A., Lenzi, A., & Gnessi, L. (2015) · Endocrine · doi:10.1007/s12020-015-0530-0 · Cited by 25
“However, since GH levels decline with aging and weight gain, and both elderly and obese individuals have a higher risk of developing cardiometabolic diseases independent of reduced GH [29], it is difficult to determine whether changes in metabolic environment are specifically related to GHD or other concomitant condit…”
BackgroundYu, J. I., Lim, D. H., Jung, S. H., Sung, K. W., Yoo, S., & Nam, H. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.016 · Cited by 21
Reinehr, T., Lindberg, A., Kołtowska‐Häggström, M., & Ranke, M. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12464 · Cited by 23
Holdaway, I. M., Hunt, P. J., Manning, P. J., Cutfield, W. S., Gamble, G. D., Ninow, N., Staples‐Moon, D., Moodie, P. M., & Metcalfe, S. (2014) · Clinical Endocrinology · doi:10.1111/cen.12691 · Cited by 20
The endocrine role of hepatokines: implications for human health and disease
Iglesias, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663353 · Cited by 25
Bonert, V. S., & Melmed, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00004-0 · Cited by 21
Self-citationBrigante, G., Diazzi, C., Ansaloni, A., Zirilli, L., Orlando, G., Guaraldi, G., & Rochira, V. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0961 · Cited by 12
Zheng, X., Cheng, Q., Long, J., Wang, Y., Gong, L., Wei, Q., Luo, R., Liao, K. T., & Ren, W. (2019) · Clinical Endocrinology · doi:10.1111/cen.13958 · Cited by 15
Biller, B. M. K., Höybye, C., Ferran, J.-M., Kelepouris, N., Nedjatian, N., Olsen, A. H., Weber, M. M., & Gordon, M. B. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad054 · Cited by 12
“AGHD may persist from childhood or can occur in adulthood due to pituitary adenomas and their related therapies, other hypothalamic-pituitary disorders, or brain trauma [1, 2].”
BackgroundIdiopathic Growth Hormone Deficiency in Adults, Ben Johnson and the Somatopause
Sönksen, P. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2025 · Cited by 10
“Idiopathic Growth Hormone Deficiency in Adults, Ben Johnson and the Somatopause Peter Sonksen, MD FRCP FFSEM Emeritus Professor of Endocrinology, St Thomas’ Hospital and King’s College, London and Visiting Professor Faculty of Medicine, Southampton University, United Kingdom In his update on the syndrome of adult GH d…”
BackgroundInfluentialNeurologic Complications of Nondiabetic Endocrine Disorders
Ishii, M. (2014) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000450966.68828.45 · Cited by 14
“presenting with seemingly nonspecific symptoms of fatigue, lack of energy, and reduced physical capacity.(10) The signs of GH deficiency are also nonspecific and may include increased adiposity (mostly central) and decreased lean mass and bone mineral density, as well as hyperlipidemia and glucose intolerance or diabe…”
BackgroundReduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
Höybye, C., Biller, B. M. K., Ferran, J.-M., Gordon, M. B., Kelepouris, N., Nedjatian, N., Olsen, A. H., & Weber, M. M. (2022) · Endocrine Connections · doi:10.1530/ec-22-0267 · Cited by 9
Prevalence and risk of complications in untreated patients with adult growth hormone deficiency
Fukuoka, H., Endo, T., Tsuboi, S., & Fujio, S. (2025) · Pituitary · doi:10.1007/s11102-025-01500-9 · Cited by 10
“Adult GH deficiency (AGHD) can be caused by an acquired impairment in the secretion of this peptide as a result of a sellar mass disorder, perisellar surgery, or radiation, as well as by traumatic brain injury and subarachnoid hemorrhage [1–4].”
Ajdžanović, V. Z., Jarić, I., Živanović, J., Šošić‐Jurjević, B., Trifunović, S. L., Tanić, N., & Milošević, V. (2014) · Acta veterinaria · doi:10.2478/acve-2014-0010 · Cited by 7
Şimşek, Y., Kaya, M. G., Tanrıverdi, F., Çalapkorur, B., Diri, H., Karaca, Z., Unluhizarci, K., & Keleştimur, F. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0142-1 · Cited by 8
“Melmed reported enhanced cardiac morbidity and increased fat mass in patients with GHD [37].”
BackgroundDiazzi, C., Brigante, G., Ferrannini, G., Ansaloni, A., Zirilli, L., Santis, M. C. D., Zona, S., Guaraldi, G., & Rochira, V. (2016) · Endocrine · doi:10.1007/s12020-016-1133-0 · Cited by 6
Soga, A., Fukuda, I., Kobayashi, S., Tahara, S., Morita, A., & Sugihara, H. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0288 · Cited by 7
Ashkenazi, N., Rosenstock, M., Hallak, H., Bassan, M., Rasamoelisolo, M., Leuschner, J., & SHINAR, D. M. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.08.001 · Cited by 5
Hypopituitarism and Growth Hormone Deficiency in Adults
Llahana, S., Marland, A., Pantovic, M., & POPOVIC, V. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_25 · Cited by 5
Unusual and lesser-known rare causes of adult growth hormone deficiency
Das, L., & Dutta, P. R. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101820 · Cited by 4
Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors
Iglesias, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154307 · Cited by 4
“After the dose stabilization, follow-up visits may be every 6 months [78,86].”
Martínez, J., & Fehrentz, J. (2020) · Australian Journal of Chemistry · doi:10.1071/ch19530 · Cited by 3
Sosial, E., & Nussinovitch, I. (2014) · Journal of Neuroendocrinology · doi:10.1111/jne.12240 · Cited by 2
Vergani, E., Bruno, C., Napodano, C., Gulli, F., Stefanile, A., Piunno, G., Basile, U., & Mancini, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110757 · Cited by 2
Herman-Bonert, V. S., & Melmed, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00023-8 · Cited by 7
Self-citationUse of l-Arginine with Growth Hormone-Releasing Hormone (GHRH) and the Endocrine Response
Brigante, G., & Rochira, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-26009-9_13 · Cited by 1
Ristić, N., Ajdžanović, V. Z., Trifunović, S. L., Tanić, N., Bujišić, N., & Milošević, V. (2015) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2015-0058
“GH cells represent the GH/ insulin-like growth factor (IGF1) axis specific operative modul, being controlled by hypothalamic, intrapituitary and peripheral signals in the function of somatic development (1).”
BackgroundБольшова, О. В., Vyshnevska, О. А., Muz, V. A., Tkachova, T. O., Malynovska, Т. M., & Samson, O. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.4.68.2015.75024
Physiopathology, Diagnosis, and Treatment of GH Deficiency
Tanrıverdi, F., & Keleştimur, F. (2017) · Endocrinology · doi:10.1007/978-3-319-38681-2_2-1
Riesgo aterogénico en el déficit de hormona de crecimiento: una mirada desde la infancia
Martínez, F. C., & Ramos, Y. P. (2018) · Ciencia y Salud · doi:10.22206/cysa.2018.v2i2.pp9-20
Erişkinde Hipopitüitarizmin Tanı ve Tedavisi
Şişman, P., & Gül, Ö. Ö. (2019) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.510272
Hormone Deficiency Syndromes of the Hypothalamic-Pituitary Axis
Polu, S., Sarmiento-Ramon, J. C., Haque, N., & Karam, S. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-62187-2_11
Growth hormone assays and dynamic tests in the diagnosis of acromegaly and GH deficiency in adults
Markkanen, H. M. (2021) · Helda - University of Helsinki Institutional Repository · Cited by 1
Physiopathology, Diagnosis, and Treatment of GH Deficiency
Tanrıverdi, F., & Keleştimur, F. (2018) · Endocrinology · doi:10.1007/978-3-319-44444-4_2
Risks and Benefits of Growth Hormone Replacement in the Elderly
Labadzhyan, A., & Melmed, S. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_31 · Cited by 2
Self-citationRen, Z., Peng, Y., Wang, Y., Shen, Y.-Y., Chen, J., Ren, W., & Liu, D. (2023) · Research Square · doi:10.21203/rs.3.rs-2636327/v1
Nadarajah, N., Ssemmondo, E., Brooks, S., Akinyombo, R., Adeleke, K. A., Deshmukh, H., & Sathyapalan, T. (2024) · Intern J Endocrinol Metab · doi:10.5812/ijem-147825
“Adult-onset idiopathic GHD on the other hand, its diagnosis may prove to be challenging due to reduced GH pulsatility and reduced peak GH response to secretagogues with increasing age (32).”
BackgroundPost-COVID-19 Condition and Endocrine Dysfunction
Xie, X., Ji, W., & Bai, G. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015260
Metadata
- Authors
- Melmed, S.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Melmed, Shlomo
- ORCID
- Melmed, Shlomo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-06-01
- Volume
- 98
- Issue
- 6
- Pages
- 2187-2197
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3667267
- OpenAlex
- W2059203397
- Semantic Scholar
- 333dabc829dcdc57a0f6e139fad0429a3141970f
- Cited by
- 58
- References
- 86
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 4 · 2014: 9 · 2013: 2
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cedars-Sinai Medical Center
- National Institutes of Health
- National Cancer Institute (R01CA075979, CA-75979)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- growth hormone secretion, somatotrophs, hypopituitarism, head and neck radiotherapy, growth hormone replacement therapy, obesity, bone mass, cardiac morbidity, diagnostic criteria
- MeSH terms
- Adult, Humans, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.